English
Regional settings| Spread | 0.20 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 153.28 |
| Open | 154.89 |
| 1-Year Change | -10.43% |
| Day's Range | 154.89 - 158.45 |
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operate its business through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
BRIEF: For the fiscal year ended 31 December 2021, Zoetis Inc revenues increased 16% to $7.78B. Net income increased 24% to $2.04B. Revenues reflect International segment increase of 20% to $3.65B, US segment increase of 14% to $4.04B, United States segment increase of 14% to $4.04B, Other emerging markets segment increase of 19% to $778M. Net income benefited from Interest Expense -Gross decrease of 2% to $244M (expense).
Class A Common Stock $.01 Par, 2/13, 5M auth., 86,100,000 issd. Insiders own less than 1%. Class B Common Stock $.01 Par, 1B auth., 413,900,000 issd.
